Company news
Alector, Inc. news in 2020
Alector, Inc.'s news releases, calls and decks from 2020, newest first.
Alector to Present at the Stifel 2020 Virtual Healthcare Conference
November 10, 2020
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 9, 2020
Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
November 1, 2020
Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
October 21, 2020
Alector to Participate at Virtual Investor Conferences in September
September 2, 2020
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
August 3, 2020
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
July 27, 2020
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
July 23, 2020
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference
July 20, 2020
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine
June 24, 2020
Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
June 2, 2020
Alector Reports 2020 First Quarter Financial Results and Business Highlights
May 12, 2020
Alector to Present at the Bank of America Securities Virtual Health Care Conference
May 6, 2020
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
March 24, 2020
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights
March 23, 2020
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
March 22, 2020
Alector to Present at the Cowen 40th Annual Health Care Conference
February 23, 2020
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia
February 4, 2020
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 2, 2020
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering
January 30, 2020
Alector Announces Upsizing and Pricing of Public Offering
January 28, 2020
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients
January 27, 2020
Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference
January 7, 2020
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
January 5, 2020